2Ricc I,Antonuzzo A,Calli L,et al.Gemcitabine monotherapy in elderly patients with advanced non-small lung cancer a multi- center phase Ⅱ study[J].Ltmg Cancer,2000,27(2):75-80.
4Schnitxcr JE,Oh P.Antibodies to SPARC inhibit albumin binding toSPARC,gp60,and microvascular endothelium[J].Am J Physiol, 1992,263(6 Pt 2): H1872-H1879.
5Rempel SA,Ge S,Gutierrez JA.SPARC: A potential diagnostic markerof invasive meningiomas[J].Clin Cancer Res,1999,5(2): 237-242.
6Porter PL,Sage EH,Lame TF, et al.Distribution of SPARC in nor mal and neoplastic human tissue[J].J Histochem Cytochem,1995, 43(8):79-88.
7Desai N,Trieu V, Yao ZW, et al.Increased antitumor activity, in tratumor paclitaxel concentrations,and endothelial cell transport ofcremophor- free,albumin-bound paclitaxel,ABI-007,compared withcremophor-based paclitaxel[J].Clin Cancer Res,2006,12(4): 1317.
8John TA,Vogel SM,Tiruppathi C,et al.Quantitative analysis of al bumin uptake and transport in the rat microvessel endothelialm- onolayer[J].Am J Physiol Lung Cell Mol Physiol,2003,284(1): L187-195.
9Porter PL,Sage EH,Lane TF, et al.Distribution of SPARC in norm- aland neoplastic human tissue[J].J Histochem Cytochem, 1995,43 (8):791-800.
二级参考文献22
1[1]Taxol(R) (paclitaxel) Injection [package insert]. Princeton, New Jersey: Bristol-Myers Squibb Co; March 2003
2[2]Lorenz W, Reimann HJ, Schmal A, et al. Histamine release in dogs by Cremophor EL and its derivatives: Oxethylated oleic acid is the most effective constituent [ J]. Agents Actions, 1977, 7 ( 1 ): 63 -67.
3[3]Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation [J]. Eur J Cancer, 2001, 37(13): 1590 - 1598.
5[5]Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to Paclitaxel: an in vitro study [J]. J Natl Cancer Inst, 1998, 90(4):300 - 305.
6[6]ten Tije AJ, Verweij J, Loos WJ, et al. Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy [J] .Clin Pharmacokinet, 2003, 42 (7): 665 - 685.
7[7]van Zuylen L, Karlsson MO, Verweij J, et al. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles [J]. Cancer Chemother Pharmacol, 2001, 47(4): 309 - 318.
8[8]Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood:clinical pharmacokinetic implications [J] . Cancer Res, 1999, 59(7): 1454 - 1457.
9[9]Ibrahim NK, Desai N, Legha S, et al. Phase Ⅰ and pharmacokinetic study of ABI-007, a Cremophor-free proteinstabilized. nanoparticle formulation of paclitaxel [J]. Clin Cancer Res, 2002, 8(5): 1038 - 1044.
10[10]Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over [J]. J Clin Oncol, 2000, 18(4): 724 - 733.
